Corporate | 28 February 2011 15:01
|
STRATEC Biomedical Systems AG / Key word(s): Dividend
STRATEC proposes increased dividend of Euro 0.50 per share Birkenfeld, February 28, 2011 The Supervisory Board and Board of Management of STRATEC Biomedical Systems AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, TecDAX) will propose a dividend of Euro 0.50 per share for the 2010 financial year for approval by the Company's shareholders at the Annual General Meeting to be held on April 14, 2011. This proposal represents an increase of 11% compared with the dividend of Euro 0.45 paid for the previous year. Hermann Leistner, Chairman of the Board of Management commented 'The 2010 financial year was once again very successful for STRATEC. As well as acquiring the former Ballista business, now STRATEC Biomedical USA, specializing in optomechanic system solutions and reader technology, STRATEC and its subsidiaries also made substantial investments in our development activities and significantly expanded our production capacities. While bearing in mind both our future growth strategy and the need to invest for the long-term, we are delighted to be able to increase our dividend for the seventh consecutive year'. Full results for the 2010 financial year and medium-term financial guidance, based on recent clients' forecasts and statements allied to the Company's current development pipeline, will be published before the German market opens on March 8, 2011. About STRATEC STRATEC Biomedical Systems AG ( www.stratec.com ) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, and are a constituent of the Deutsche Börse TecDAX. The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical Systems AG as well as subsidiaries and second-tier subsidiaries in Germany, the USA, the UK, Switzerland and Romania. Further information can be obtained from:
STRATEC Biomedical Systems AG
End of Corporate News 28.02.2011 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
| Language: | English | |
| Company: | STRATEC Biomedical Systems AG | |
| Gewerbestraße 37 | ||
| 75217 Birkenfeld | ||
| Deutschland | ||
| Phone: | +49 (0)7082 7916 0 | |
| Fax: | +49 (0)7082 7916 999 | |
| E-mail: | info@stratec-biomedical.de | |
| Internet: | www.stratec-biomedical.de | |
| ISIN: | DE0007289001 | |
| WKN: | 728900 | |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart | |
| End of News | DGAP News-Service |
|
|
| 113759 28.02.2011 |